Therapeutic startup Celularity announced Thursday morning that it has received US FDA approval to begin clinical trials of its proposed stem cell treatment for coronavirus
The human placenta contains stem cells (hematopoietic stem cells and mesenchymal stem cells), and umbilical cord blood contains many hematopoietic stem cells, which may be of great importance in hematopoietic stem cell transplants
Hematopoietic stem cells are the source of all blood. All cells circulating in blood vessels, such as red blood cells, white blood cells, and platelets, are differentiated from hematopoietic stem cells
Among these are immune cells called NK cells, which attack and eliminate foreign substances, pathogens, and viruses that enter the body
Clinical trials were planned to determine the effectiveness of this drug when used to treat coronavirus infection, and the FDA (a US government agency equivalent to Japan's Ministry of Health, Labor and Welfare) gave its approval
It is expected to be administered to up to 86 patients from now on

Quoted from:
[New York Times report]

Quoted from:
[Forbes article]
https://www.forbes.com/sites/alexknapp/2020/04/02/fda-gives-green-light-to-test-a-treatment-against-covid-19-coronavirus-that-flattens-the-curve-in-patients/#7a55a1354b57

Quoted from:
[Video of a conversation between the developer and the Mayor of New York]